"MATCH": Multi-Antigen T-Cell Engagers
Oncotherapy
Multi-Specific Immunotherapy by Predictive Modeling
High-Throughput Bispecific Antibody Screening
MATCH provides a platform targeting system capable of treating B-cell leukemias, lymphomas, and multiple myeloma through multi-specific targeting.
High-Throughput Bispecific Antibody Screening
Multi-Specific Immunotherapy by Predictive Modeling
High-Throughput Bispecific Antibody Screening
MATCH is a platform capable of producing any bispecific combination of antibody binding fragments.
Multi-Specific Immunotherapy by Predictive Modeling
Multi-Specific Immunotherapy by Predictive Modeling
Multi-Specific Immunotherapy by Predictive Modeling
Thera-T is developing theranostic AI/ML models to usher in a new era of personalized bispecific immunotherapeutics.
Published Works
ACS Nano
Multi-Antigen T-Cell Hybridizers: A Two-Component T-Cell-Activating Therapy
Nanomedicine: NBM
Two-Component T-Cell Immunotherapy Enables Antigen Pre-Targeting To Reduce Cytokine Release Without Forfeiting Efficacy
Manuscript In Preparation
Manuscript In Preparation
Multi-Specific T-Cell Engagers: A Tool Towards Computer-Assisted Personalized Medicine
Team
Thomas Gambles, PhD
Thomas Gambles, PhD
Thomas Gambles, PhD
President & Co-Founder
Isaac Kendell, MS
Thomas Gambles, PhD
Thomas Gambles, PhD
Chief Engineer
Steven Valdez, PhD
Thomas Gambles, PhD
Steven Valdez, PhD
Business Operations
Advisory Board
Jindřich Kopeček, PhD
Mike McCullar, PhD MBA
Jindřich Kopeček, PhD
Co-Founder & Scientific Advisor
David Bearss, PhD
Mike McCullar, PhD MBA
Jindřich Kopeček, PhD
Scientific & Business Advisor
Mike McCullar, PhD MBA
Mike McCullar, PhD MBA
Mike McCullar, PhD MBA
Business Advisor